Long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are gaining traction in the COPD market, and both LAMAs and LABA/inhaled corticosteroid (ICS) FDCs are threatened by uptake of these therapies. However, many patients persist on long-acting therapies for long periods of time before switching, making it difficult for new therapies to gain a foothold. Due to the progressive and irreversible nature of COPD, many patients eventually end up being prescribed a combination including a LABA, LAMA, and ICS, giving the first triple therapy combination in its class, Trelegy, a promising market position.
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed COPD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed COPD patients?
- How have LABA/LAMAFDCs been integrated into the treatment algorithm?
- What percentage of COPD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of COPD patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients with COPD?
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.